GLP-1 Drugs and Cognitive Function: What Systematic Reviews Show So Far | Research

The takeaway

An umbrella review of systematic reviews and meta-analyses finds emerging evidence that GLP-1 RAs may benefit cognitive function in people with diabetes and cognitive impairment.

Emerging cognitive benefit
Systematic reviews suggest GLP-1 RAs may improve cognition in T2DM patients with cognitive impairment

What the researchers found

Available systematic reviews suggest GLP-1 RAs may have cognitive benefits in people with T2DM and cognitive impairment, though evidence remains limited.

Why it matters

With millions of diabetic patients at cognitive risk, any proven cognitive benefit of GLP-1 RAs — which they're already taking — would have enormous public health impact.

How the study worked

Systematic review of systematic reviews and meta-analyses; Web of Science and MEDLINE searched through July 2025; three independent reviewers.

What this study cannot tell us

Umbrella review limited by quality of included reviews; primary studies often small with heterogeneous cognitive measures; publication bias possible.

How to read the evidence

Umbrella review (review of reviews) — highest level of evidence synthesis, but limited by the quality and quantity of primary studies.

When this study was published

Published 2026 in Journal of Affective Disorders. Searches through July 2025.

The bigger picture

The cognitive benefits of GLP-1 RAs, if confirmed, would add yet another dimension to their therapeutic value — from diabetes drugs to metabolic, cardiovascular, renal, and potentially cognitive protective agents.

Questions still open

Will dedicated cognitive endpoint trials of GLP-1 RAs in T2DM be launched?
Which cognitive domains show the most improvement with GLP-1 RA treatment?

Common questions

Can GLP-1 drugs help with memory problems?

Preliminary evidence from multiple review studies suggests GLP-1 drugs may have cognitive benefits for people with diabetes and thinking problems, though more research is needed to confirm this.

Should diabetic patients with memory issues switch to GLP-1 drugs?

While the evidence is promising, it's not yet strong enough to recommend GLP-1 RAs specifically for cognitive benefits. However, for patients who need diabetes treatment, the potential cognitive upside adds to the rationale for choosing GLP-1 RAs.

Read the original research

The effect of glucagon-like peptide 1 (GLP-1) receptor agonists on cognition: A systematic review of systematic reviews and meta-analyses.

Journal of affective disorders, 402, 121310

View on PubMed ↗Publisher’s paper ↗

Citation

Ballum, Hana; Dri, Christine; Liao, Sonya; Yu, Minyi; Le, Gia Han; Wong, Sabrina; Teopiz, Kayla M; Kwan, Angela T H; Ho, Roger; Choi, Hayun; Rosenblat, Joshua D; Vinberg, Maj; K Y Lo, Heidi; McIntyre, Roger S. (2026). The effect of glucagon-like peptide 1 (GLP-1) receptor agonists on cognition: A systematic review of systematic reviews and meta-analyses.. Journal of affective disorders, 402, 121310. https://doi.org/10.1016/j.jad.2026.121310